Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Blood (2024) 144 (Supplement 1): 470.

https://doi.org/10.1182/blood-2024-199723

Published: 2024

Journal Articles

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Blood (2024) 144 (Supplement 1): 748.

https://doi.org/10.1182/blood-2024-198021

Published: 2024

Journal Articles

Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

Blood (2024) 144 (Supplement 1): 4388.

https://doi.org/10.1182/blood-2024-198018

Published: 2024

Journal Articles

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Nina Wagner-Johnston, Opeyemi Jegede, Stephen E Spurgeon, Kami J. Maddocks, David T Yang, Justin Romanoff, Jonas Paludo, Paolo F. Caimi, Nancy L. Bartlett, Patrick M. Reagan, Yazeed Sawalha, Marc Hoffmann, Boyu Hu, Ashraf R Aziz, Helga Marques, Lale Kosakoglu Shields, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl

Blood (2024) 144 (Supplement 1): 236.

https://doi.org/10.1182/blood-2024-194641

Published: 2024

Journal Articles

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Jennifer E. Amengual, Hongli Li, Patrick M. Reagan, Tareq Al Baghdadi, Hayder Saeed, Joseph M Unger, Alexey Danilov, Michael Leblanc, Jonathan W. Friedberg, Sonali M. Smith

Blood (2024) 144 (Supplement 1): 3123.2.

https://doi.org/10.1182/blood-2024-199784

Published: 2024

Journal Articles

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Anita Kumar, Ashlee Joseph, Brian T. Hill, Taylor R. Brooks, David A. Bond, Kami J. Maddocks, Alexey Danilov, Christine McCarthy, Jia Ruan, Imran A. Nizamuddin, Brad S. Kahl, Natalie S. Grover, Nazneen B. Khan, Evguenia Ouchveridze, Aung M. Tun, Philip Young, Craig A. Portell, Zoey I. Harris, Javier L. Munoz, Patrick M. Reagan, Georgio Pongas, Izidore S. Lossos, Christine E. Ryan, Reid W. Merryman, Firas Baidoun, Muhamad Alhaj Moustafa, Drew Gerber, Sabarish R. Ayyappan, Brian K. Link, Arash Velayati, Irl Brian Greenwell, Lauren G Banaszak, Priyanka A Pophali, Anthony C. Stack, Marcus R. Messmer, Mayur Narkhede, Amitkumar N. Mehta, Preetesh Jain, Michael L. Wang, Tamara K. Moyo, Nilanjan Ghosh, Rahul S. Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob Anna, Alexander V. Stanisic, Reem Karmali, Laveniya Kugathasan, Diego Villa, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin

Blood (2023) 142 (Supplement 1): 300.

https://doi.org/10.1182/blood-2023-182942

Published: 2023

Journal Articles

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Blood (2023) 142 (Supplement 1): 105.

https://doi.org/10.1182/blood-2023-180952

Published: 2023

Journal Articles

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Olalekan O. Oluwole, Patrick M. Reagan, David B. Miklos, Frederick L. Locke, Andre Goy, Caron A. Jacobson, Javier L. Munoz, Edouard Forcade, Max S. Topp, Dan Zheng, Ana Nunes, Wangshu Zhang, Rhine R. Shen, Ioana Kloos, Marie José Kersten, Michael L. Wang

Blood (2023) 142 (Supplement 1): 2120.

https://doi.org/10.1182/blood-2023-174681

Published: 2023

Journal Articles

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Blood (2023) 142 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2023-179868

Published: 2023

Journal Articles

Efficacy and Safety of a Third Generation CD20 CAR-T (MB-106) for Treatment of Relapsed/Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Phase-1 Results from a Multicenter Trial

Mazyar Shadman, Paolo F. Caimi, Susan M. O'Brien, Patrick M. Reagan, Bruce Dezube, Punya Navaratnarajah, Tripti Gaur, Suzanne Petrossian, Anthony Germani, Brian G Till, Jeremy S. Abramson

Blood (2023) 142 (Supplement 1): 2102.

https://doi.org/10.1182/blood-2023-175007

Published: 2023

Journal Articles

Ilyad: A Phase III Double Blind, Randomized Trial Evaluating Vitamin D (Cholecalciferol) in Patients with Low Tumor-Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab Therapy

Jonathan W. Friedberg, Michael T. Brady, Strawderman Myla, Brad S. Kahl, Izidore S. Lossos, Jonathon B. Cohen, Patrick M. Reagan, Carla Casulo, Barbara L. Averill, Brian K. Link, Paul M. Barr, John P. Leonard, John M. Ashton, Derick R Peterson, Loretta J. Nastoupil

Blood (2023) 142 (Supplement 1): 606.

https://doi.org/10.1182/blood-2023-178088

Published: 2023

Journal Articles

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Blood (2023) 141 (19): 2307–2315.

https://doi.org/10.1182/blood.2022018893

Published: 2023

Includes: Supplemental data

Journal Articles

Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)

Javier Munoz, Patrick M. Reagan, Andre H. Goy, David B. Miklos, Dan Zheng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Marie José Kersten, Michael Wang

Blood (2022) 140 (Supplement 1): 9320–9322.

https://doi.org/10.1182/blood-2022-158097

Published: 2022

Journal Articles

Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis

Arushi Khurana, Raphael Mwangi, Loretta J. Nastoupil, Patrick M. Reagan, Umar Farooq, Jason T. Romancik, Timothy J. McDonnell, Shaun M Riska, Izidore S. Lossos, Brad S. Kahl, Peter Martin, Thomas E. Witzig, James R. Cerhan, Christopher R. Flowers, Matthew J. Maurer, Grzegorz S. Nowakowski

Blood (2022) 140 (Supplement 1): 2056–2058.

https://doi.org/10.1182/blood-2022-169433

Published: 2022

Journal Articles

Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study

Armin Ghobadi, Javier Munoz, Jason Westin, Frederick L. Locke, David B. Miklos, Aaron P. Rapoport, Miguel-Angel Perales, Patrick M. Reagan, Joseph P. McGuirk, Caron A. Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O. Oluwole

Blood (2022) 140 (Supplement 1): 1595–1597.

https://doi.org/10.1182/blood-2022-158303

Published: 2022

Journal Articles

Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence

Siba El Hussein, Pingjun Chen, Morteza Salehjahromi, Hong Fang, Wei Wang, Sanam Loghavi, Patrick M. Reagan, Jonathan W. Friedberg, Richard Burack, Andrew G Evans, L. Jeffrey Medeiros, Jia Wu, Joseph D. Khoury

Blood (2022) 140 (Supplement 1): 7836–7837.

https://doi.org/10.1182/blood-2022-166610

Published: 2022

Journal Articles

Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial

Sven de Vos, Patrick M. Reagan, Manish R. Patel, Nakhle S. Saba, Andrew Mortlock, Virginie Cerec, Veerendra Munugalavadla, Melih Acar, Barrett Nuttall, David Jenkins, Rafael White, Megan Callahan, Alessandra Forcina, Mark Roschewski, Ian W. Flinn

Blood (2022) 140 (Supplement 1): 6635–6637.

https://doi.org/10.1182/blood-2022-162447

Published: 2022

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Blood (2022) 140 (Supplement 1): 6623–6626.

https://doi.org/10.1182/blood-2022-157761

Published: 2022

Journal Articles

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Blood (2022) 139 (9): 1330–1339.

https://doi.org/10.1182/blood.2021013289

Published: 2022

Includes: Supplemental data

Journal Articles

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2.

https://doi.org/10.1182/blood-2021-148039

Published: 2021

NARROW

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Efficacy and Safety of a Third Generation CD20 CAR-T (MB-106) for Treatment of Relapsed/Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Phase-1 Results from a Multicenter Trial

Ilyad: A Phase III Double Blind, Randomized Trial Evaluating Vitamin D (Cholecalciferol) in Patients with Low Tumor-Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab Therapy

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)

Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis

Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study

Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence

Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only